Welcome to the e-CCO Library!

P378: Renal AA amyloidosis associated with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bibani N., Gharbi O., Trad D., Sabbah M., Ouakaa A., Gargouri D., Elloumi H., Kharrat J.

Created: Wednesday, 20 February 2019, 10:36 AM
P378: The outcomes of a clinical care pathway for inflammatory bowel disease surgery
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Platt*1, A. Lightner2, R. Jacobs1, D. Sagar1, W. van Deen1, T. Hommes1, S. Reardon3, J. Sack3, D. Hommes1

Created: Friday, 22 February 2019, 9:49 AM
P379 Surveillance with chromoendoscopy to detect new dysplasia in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Villar Lucas, R. Quiñones Castro, L. Vaquero Ayala, P. Suárez Álvarez, M.J. Fernández Gundin, M. Sierra Ausín

Created: Thursday, 30 January 2020, 10:12 AM
P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Latremouille-Viau1, R. Burne1, S. Shi1, S. Adsul2, H. Patel*2

Created: Friday, 22 February 2019, 9:41 AM
P379: Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Danese, S.(2,3);Cohen, B.L.(4);Magro, F.(5);Chen, Y.(6);Ha, C.(7);Dubcenco, E.(8);Lacerda, A.P.(8);Marced, E.(8);Oomen, J.(8);Garrison, A.(8);Peyrin-Biroulet, L.(9);
Created: Friday, 14 July 2023, 11:05 AM
P379: Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. S. Prüß*, A. Farmer, B. Siegmund

Created: Friday, 22 February 2019, 9:49 AM
P379: Infliximab or adalimumab: Which should be used first for Crohn’s disease? A multicentre retrospective observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Takahashi1*, T. Inokuchi2, S. Hiraoka2, T. Toyokawa3, S. Takagi4, K. Takemoto5, J. Miyaike6, T. Fujimoto7, R. Higashi8, H. Yasuhara9, T. Nawa10, S. Suzuki11, J. Kato12, H. Okada2

Created: Thursday, 21 February 2019, 9:14 AM
P379: Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Johnson H., Wade K., Hovell C., Weaver S., McLaughlin S.

Created: Wednesday, 20 February 2019, 10:36 AM
P379: Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Stack, R.(1);Fennessy, A.(1);Cullen, G.(1);Mulcahy, H.(1);Sheridan, J.(1);Kevans, D.(1);Doherty, G.(1);
Created: Friday, 11 February 2022, 3:52 PM
P379: Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.
Year: 2021
Source: ECCO'21 Virtual
Authors: Hilley, P.(1);Li Wai Suen, C.(1,2);Srinivasan, A.(1,2);Choy, M.C.(1,2);De Cruz, P.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P380 What is the optimal dose of thiopurinic drugs (azatioprine) in patients with inflammatory bowel disease under treatment combined with anti-TNFα (infliximab/adalimumab)?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. LUCAS RAMOS, C. Suarez Ferrer, M. Sanchez Azofra, J. Poza Cordón, E. Martín Arranz, M.D. Martin Arranz

Created: Thursday, 30 January 2020, 10:12 AM
P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese*1, A. Hart2, A. Dignass3, G. Fiorino1, E. Louis4, G. D'Haens5, I. Dotan6,7, G. Rogler8, K. Paridaens9, L. Peyrin-Biroulet10

Created: Friday, 22 February 2019, 9:41 AM
P380: Assessment of the awareness and education of vaccination in our IBD cohort: an observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Maheshwari P., Palaniappan S.K., Moran C., Forry M., Parihar V., Hall B., Reilly M., O'Toole A.

Created: Wednesday, 20 February 2019, 10:36 AM
P380: Changes in faecal microbiome and metabolome are more pronounced in Crohn's disease patients who adhered to the CD-TREAT diet and responded by calprotectin.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Svolos, V.(1)*;Hansen, R.(2);Russell, R.K.(3);Gaya, D.R.(4);John Paul, S.(5);Macdonald, J.(5);Wilson, D.(3);Henderson, P.(3);Din, S.(6);Ho, G.T.(6);Quince, C.(7);Ijaz, U.Z.(8);Milling, S.(9);Nichols, B.(1);Papadopoulou, R.(1);McKirdy, S.(1);Gervais, L.(2);Shields, S.(5);Gerasimidis, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P380: Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Szymanska*1, M. Dadalski2, S. Szymanska3, W. Grajkowska3, M. Pronicki3, K. Jaroslaw2

Created: Friday, 22 February 2019, 9:49 AM
P380: Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologics
Year: 2021
Source: ECCO'21 Virtual
Authors: Temido, M.J.(1);Portela, F.(1);Lopes, S.(1);Mendes, S.(1);Ferreira, M.(1);Ferreira, M.(1);Figueiredo, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P380: Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Feagan, B.G.(1);Colombel, J.F.(2);Panaccione, R.(3);Schreiber, S.(4);Ferrante, M.(5);Kamikozuru, K.(6);Lee, W.J.(7);Griffith, J.(7);Kligys, K.(7);Kalabic, J.(8);Chen, N.(7);Dubinsky, M.(2);
Created: Friday, 11 February 2022, 3:52 PM
P380: Risk factors for poor postoperative outcome in patients with Crohn’s disease undergoing ileocaecal resection
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Labidi1*, M. Ben Abbes1, S. Hamdi1, H. Maghrebi2, N. Ben Mustapha1, M. Fekih1, L. Zouiten1, M. Serghini1, Z. Ben Safta2, J. Boubaker1

Created: Thursday, 21 February 2019, 9:14 AM
P381 Use of ustekinumab in Crohn’s disease: Singapore largest single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H.H. Shim1, S.C. Kong1, W.C. Ong2, T.G. Lim2, P.W. Chan1

Created: Thursday, 30 January 2020, 10:12 AM
P381: Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panaccione R.*1, Rutgeerts P.2, Sandborn W.3, Schreiber S.4, Colombel J.-F.5, Berg S.6, Maa J.-F.7, Petersson J.7, Robinson A.M.7

Created: Wednesday, 20 February 2019, 10:36 AM